Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Sun

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Annals of Surgical Oncology|March 11, 2020
International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian PatientsJüri Teras, Hidde M Kroon, John T Miura, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Annals of Surgical Oncology|September 12, 2020
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and AustraliaMichael J Carr, James Sun, Hidde M Kroon, et al.
The Oncologist|September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation SignaturesAdrienne Johnson, Eric Severson, Laurie Gay, et al.
Journal of the National Cancer Institute|January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal CancerFilippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Nature Biotechnology|October 22, 2013
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingGarrett M Frampton, Alex Fichtenholtz, Geoff A Otto, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Annals of Surgical Oncology|March 11, 2020
International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian PatientsJüri Teras, Hidde M Kroon, John T Miura, et al.
Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.
Annals of Surgical Oncology|September 12, 2020
Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and AustraliaMichael J Carr, James Sun, Hidde M Kroon, et al.
The Oncologist|September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation SignaturesAdrienne Johnson, Eric Severson, Laurie Gay, et al.
Journal of the National Cancer Institute|January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal CancerFilippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Lancet (London, England)|September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialRobert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Nature Biotechnology|October 22, 2013
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingGarrett M Frampton, Alex Fichtenholtz, Geoff A Otto, et al.
Pageof 10